Table 3

Types and clinical use of anti-VEGF mAbs and multi-kinase inhibitors

DrugType and targetDisease, stage and references
Avastin/BevacizumabmAb against VEGF75Multiple tumour types including: CRC, NSCLC, and breast cancer (FDA app)
Pazopanib/ GW786034TKI of VEGFR-1,-2,-3, PDGFRα,-β, Kit, FGFR-1,-3, Itk, Lek, c-Fms76Multiple tumour types including: solid tumours (with paclitaxel/carboplatin, Phase I), RCC (FDA app)77
Imatinib/STI157TKI of PDGFRβ ,Bcr-Abl, Kit78Multiple tumour types including: GIST (FDA app)78
Sunitinib/SU11248TKI of VEGFR1-,2,-3, PDGFRα,-β, Kit, FLT-3, CSF1R, RET78GIST (imatinib resist; FDA app), RCC (FDA app), NSCLC (Phase III)78 79
MotesanibTKI of VEGFR1,-2, PDGFRβ, Kit, RET80NSCLC (with carboplatin/paclitaxel, Phase III), breast cancer (with docetaxel/paclitaxel, Phase I/II)80–82
SorafenibTKI of VEGFR2,-3, PDGFRβ Kit, RET, B-Raf, FLT-378 83Multiple tumour types including: RCC (FDA app), HCC (FDA app)83
  • CSF1R, colony-stimulating factor 1 receptor; CRC, colorectal carcinoma; FDA app, Food and Drug Administration approved; FLT-3, FMS-like tyrosine kinase-3; GIST, gastrointestinal stromal tumour; HCC, hepatocellular carcinoma; Itk, interleukin-2 receptor inducible T-cell kinase; Lek, leucocyte-specific protein tyrosine kinase; NSCLC, non-small cell lung cancer; PDGFR/PDGFR-α/β, platelet-derived growth factor receptor-α/β; RCC, renal cell carcinoma; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; mAb, monoclonal antibody; TKI, tyrosine kinase inhibitors; FGFR, fibroblast growth factor receptor; RET, rearranged during transfection.